135 related articles for article (PubMed ID: 9681205)
1. Effect of the 5 alpha-reductase inhibitor PNU 156765, alone or in combination with flutamide, in the Dunning R3327 prostatic carcinoma model in rats.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Chemotherapy; 1998; 44(4):284-92. PubMed ID: 9681205
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Cancer Chemother Pharmacol; 2000; 45(1):31-7. PubMed ID: 10647498
[TBL] [Abstract][Full Text] [Related]
4. Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
Zaccheo T; Giudici D; di Salle E
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):193-8. PubMed ID: 9605414
[TBL] [Abstract][Full Text] [Related]
5. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Zaccheo T; Giudici D; di Salle E
Prostate; 1997 Feb; 30(2):85-91. PubMed ID: 9051146
[TBL] [Abstract][Full Text] [Related]
6. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat.
di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
[TBL] [Abstract][Full Text] [Related]
8. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE
Prostate; 1991; 18(3):215-27. PubMed ID: 1850515
[TBL] [Abstract][Full Text] [Related]
9. Response of rat ventral prostate to a new and novel 5 alpha-reductase inhibitor.
Brooks JR; Baptista EM; Berman C; Ham EA; Hichens M; Johnston DB; Primka RL; Rasmusson GH; Reynolds GF; Schmitt SM; Arth GE
Endocrinology; 1981 Sep; 109(3):830-6. PubMed ID: 7262023
[No Abstract] [Full Text] [Related]
10. Sequential androgen blockade: a biological study in the inhibition of prostatic growth.
Fleshner NE; Trachtenberg J
J Urol; 1992 Dec; 148(6):1928-31. PubMed ID: 1331549
[TBL] [Abstract][Full Text] [Related]
11. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
Imada S; Akaza H; Ami Y; Koiso K; Ideyama Y; Takenaka T
Eur Urol; 1997; 31(3):360-4. PubMed ID: 9129932
[TBL] [Abstract][Full Text] [Related]
12. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
[TBL] [Abstract][Full Text] [Related]
13. Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA.
Martel C; Trudel C; Couet J; Labrie C; Bélanger A; Labrie F
Mol Cell Endocrinol; 1993 Feb; 91(1-2):43-9. PubMed ID: 8472853
[TBL] [Abstract][Full Text] [Related]
14. Effect of early exposure of flutamide on subsequent growth of transplantable rat prostatic tumor (dunning R-3327).
Lee SZ; Sato N; Suzuki H; Watabe Y; Masai M; Shimazaki J
Prostate; 1994 Apr; 24(4):197-203. PubMed ID: 8146068
[TBL] [Abstract][Full Text] [Related]
15. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Tomura A; Kuroiwa S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
[TBL] [Abstract][Full Text] [Related]
16. Effects of flutamide and finasteride on rat testicular descent.
Spencer JR; Torrado T; Sanchez RS; Vaughan ED; Imperato-McGinley J
Endocrinology; 1991 Aug; 129(2):741-8. PubMed ID: 1677329
[TBL] [Abstract][Full Text] [Related]
17. Combination of an antiandrogen and a 5 alpha-reductase inhibitor: a further step towards total androgen blockade?
Labrie C; Trudel C; Li S; Martel C; Couêt J; Labrie F
Endocrinology; 1991 Jul; 129(1):566-8. PubMed ID: 2055205
[TBL] [Abstract][Full Text] [Related]
18. Effect of cyproterone acetate in comparison to flutamide on the ventral prostate of adult male castrated Copenhagen-Fisher rats and on Dunning R-3327 H tumors.
Donn F; Becker H; Klosterhalfen H; Klein H
Andrologia; 1989; 21(5):462-7. PubMed ID: 2530921
[TBL] [Abstract][Full Text] [Related]
19. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer.
Juniewicz PE; Fetrow N; Marinelli J; Wolf M; Young E; Lamb J; Isaacs JT
Prostate; 1991; 18(2):105-15. PubMed ID: 2006117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
